Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-20
2005-09-20
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
06946438
ABSTRACT:
The present invention relates to a new means for the treatment of focal ischemic cerebral infarction (ischemic stroke). It has been found that reduction of α2-antiplasmin leads to a significantly smaller focal cerebral infarct size. The invention therefore provides the use of compounds that reduce α2-antiplasmin concentration or activity in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).
REFERENCES:
patent: 0631786 (1998-06-01), None
patent: 9812329 (1998-03-01), None
Bork (2000) “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle.” Genome Research 10:398-400.
Skolnick and Fetrow (2000) “From gene to protein structure and function: novel applications of computational approaches in th genomic era.” Trends in Biotech. 18(1): 34-39.
Doerks et al., (Jun. 1998) “Protein annotation: detective work for function prediction.” Trends in Genetics 14(6): 248-250.
Smith and Zhang (Nov. 1997) “The challenges of genome sequence annotation or ‘The devil is in the details’.” Nature Biotechnology 15:1222-1223.
Brenner (Apr. 1999) “Errors in genome annotation.” Trends in Genetics 15(4): 132-133.
Bork and Bairoch (Oct. 1996) “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics 12(10): 425-427
Lapchak et al. (Sep. 2002) “Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits.” Stroke 33(9): 2279-2284.
Bell (1997) “Evaluation of Thrombolytic Agents.” Drugs 54(Supplement 3): 11-17.
Smalling (Nov.15, 1997) “A fresh look at the molecular pharmacology of plasminogen activators: From theory to test tube to clinical outcomes.” Am. J. Health-Syst. Pharm. 54(Suppl. 1): S17-S22.
Nagai et al. (May 15, 2001) “Depletion of circulating a2-antiplasmin by intravenous plasmin or immunoneutralizt6oin reduce focal cerebral schemic injury in the absence of arterial recanalization” . Blood 97(10): 3086-3092.
Reddy (Jan. 1998) “Newer Thrombolytic drugs for acute myocardial infarction” Indian Journal of Experimental Biology 36(1): 1-15.
Stedman's Medical Dictionary, 2002 Physician's Desk Reference Medical Economics Company Inc.
Rahman et al. (2001) Antifibrinolytic Effect of Single apo(a) kringle domains: Relationship to fibrinogen binding Protein Engineering 14(6): 427-438.
Wells (1990) Additivity of Mutational Effects in Proteins Biochemistry 29(37): 8509-8517.
Ngo et al. (1994) Coputational Complexity. Protein Structure Prediction, and the Levinthal Paradox The Protein Folding Problem and Tertiary Structure Prediction Chapter 14 pp. 433-506.
Butte, A. et al., “Alpha2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.”Circulation 95(7), 1886-1891(1997).
Reed, G., “Functional characterization of monoclonal antibody inhibitors of alpha2-antiplasmin that accelerate fibrinolysis in different animal plasmas.”Hybridoma 16(3):281-286 (1997).
Nagai, N.; et al., “Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.”Circulation 99(18):2440-2444(1999).
Collen, D. “Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent.”Nature Medicine 4(3): 279-284 (1998).
Coyle. J. T. et al. “Oxidative stress, glutamate and neurodegenerative disorders,”Science 262: 689-695 (1993).
Coyle. J. T. et al. “In situ injection of kainic acid: a new method for selectively lesioning neuronal cell bodies while sparing axons of passage”J Comp Neurol 180:301-323 (1978).
Tsirka, S.E. et al. “Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator.”Nature377: 340-344(1995).
Tsirka. S.E. et al. “An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus.”J Neurosci17(2):543-552 (1997).
Tsirka S.E. et al. “Neuronal cell death and t-PA,”Nature384: 123-124 (1996).
Chen, Z.L. et al. “Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin.”Cell91:917-925 (1997).
Wang. Y.F. et al. “Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPa-deficient mice.”Nature Medicine4(2): 228-231(1998).
Nagai, N. et al. “Comparative effects of tissue-type plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models,”Circulation100: 2541-2546 (1999).
The National Institute of Neurological Disorders and Stroke rt-Pa Stroke Study Group “Tissue plasminogen activator for acute ischemic stroke.”N Engl J Med333(24): 1581-1587 (1995).
Hacke, W. et al. for the ECASS Study Group “Intravenous thrombolysis with recombinant tissue plasminogen activation for acute hemispheric stroke: the European Cooperative Acute Stroke Sudy (ECASS),”J Am Med Ass 274(13):1017-1025 (1995).
Collen, D. et al “Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma,”Blood53(2):313-324 (1979).
Carmeliet P. et al. “Physiological consequences of loss of plasminogen activator gene function in mice,”Nature368: 419-424 (1994).
Carmeliet, P. et al. “Plasminogen activator inhibitor-1 gene-deficient mice: I. Generalization by homologous recombination and characterization,”J Clin Invest92:2746-2755 (1993).
Carmeliet, P. et al. “Plasminogen activator inhibitor-1 gene deficent mice: II. Effects on hemostatis, thrombosis and, thrombolysis,”J Clin Invest92:2756-2760 (1993).
Ploplis, V.A. et al. “Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice,”Circulation92(9): 2585-2593 (1995).
Lijnen, H.R. et al. “Alpha2-antiplasmin gene-deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding,”Blood93(7):2274-2281 (1999).
Dewerchin, M. et al. “Generation and characterization of urokinase receptor-deficient mice,”J Clin Invest97(3):870-878 (1996).
Lijnen, H. R. et al. “Amino-acid sequence of human Alpha2-antiplasmin,”Eur J Biochem166:565-574 (1987).
McGrory, W.J. et al. “A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5.”Virology163:614-617 (1988).
Gomez-Foix, A.M. et al. “Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism,”J Biol Chem267(35):25129-25134 (1992).
Graham, F.L. et al. “Characteristics of a human cell line transformed by DNA from human adenovirus type 5,”J Gen Virol36: 59-72 (1977).
Gerard, R.D., Meidel, R.S. “Adenovirus vectors. In: Hames, B.D., Glover, D. (eds.) DNA Cloning 4—A practical approach: mammalian systems,” Oxford, UK, pp. 285-306 (1995).
Alcorn, J.L. et al. “Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene,”Mol Endocrinol7(8): 1072-1085 (1993).
Kopler, W.P. et al. “Adenovirus-mediated transfer of gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol.”Circulation90(3): 1319-1327 (1994).
Carmeliet, P. et al. “Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice,”Blood90(4): 1527-1534 (1997).
Carmeliet, P. et al. “Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation,”Circulation96(9): 3180-3191 (1997).
Deutsch, D.G. et al. “Plasminogen purific
Collen Désiré José
Nagai Nobuo
Collen Desire Jose
Kemmerer Elizabeth
Leuven Research & Development VZQ
Nichols Christopher James
Webb Ziesenheim & Logsdon Orkin & Hanson, P.C.
LandOfFree
Use of compounds that reduce alpha2-antiplasmin in vivo for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of compounds that reduce alpha2-antiplasmin in vivo for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of compounds that reduce alpha2-antiplasmin in vivo for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3381477